CAMG Solamere Management’s Novartis NVS Stock Holding History

CAMG Solamere Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,281	Closed	-$253K	–	111
2018 Q3	$253K	Sell	3,281 -2,116	-39%	-$156K	0.13%	102
2018 Q2	$367K	Sell	5,397 -3,142	-37%	-$217K	0.18%	96
2018 Q1	$614K	Buy	8,539 +101	+1%	+$7.69K	0.28%	89
2017 Q4	$693K	Sell	8,438 -419	-5%	-$31.6K	0.31%	85
2017 Q3	$681K	Sell	8,857 -61	-0.7%	-$4.61K	0.34%	86
2017 Q2	$669K	Sell	8,918 -85	-0.9%	-$6.02K	0.38%	81
2017 Q1	$595K	Sell	9,003 -128	-1%	-$8.53K	0.35%	85
2016 Q4	$595K	Buy	+9,131	New	+$592K	0.42%	78

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

CAMG Solamere Management's NVS Position: Q4 2018 in Review

CAMG Solamere Management sold out of Novartis (NVS) in Q4 2018, closing a stake of 3,281 shares — an estimated $253K sold.

CAMG Solamere Management first reported a position in NVS in Q4 2016 and held it in 8 quarters. The position peaked at $693K in Q4 2017. 1,087 funds tracked by Wall St. Rank hold NVS as of Q4 2018.

CAMG Solamere Management reported no remaining Novartis position as of Q4 2018 after selling out during the quarter.
CAMG Solamere Management sold 3,281 Novartis shares in Q4 2018, an estimated $253K.
CAMG Solamere Management first reported a position in Novartis in Q4 2016 and held it in 8 quarters.
CAMG Solamere Management's Novartis position peaked at $693K in Q4 2017.
1,087 funds tracked by Wall St. Rank held Novartis as of Q4 2018.

Based on CAMG Solamere Management's 13F filing for Q4 2018, filed 14 Feb 2019.